Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Treating ovarian cancers with PARP inhibitors

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 2614

Lisa Marie Juden - Dana-Farber Cancer Institute, Boston, MA

Lisa Marie Juden speaks to ecancer at ONS 2019 about how PARP inhibitors are used to treat ovarian cancers.

She explains how PARP inhibitors work and which drugs are currently approved for which patients.

Lisa concludes by describing the benefits of oncology nurses being aware of PARP inhibitors.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation